Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma
Melanoma remains a highly aggressive malignancy, and many patients fail to achieve durable benefit despite immune checkpoint inhibitor (ICI) therapy. ICIs improve outcomes but lack tumor specificity and do not directly recruit T-cells to tumor cells resulting in substantial side effects, highlighting the need for targe...